Association of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study

IF 1.5 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Gaceta Sanitaria Pub Date : 2025-01-01 DOI:10.1016/j.gaceta.2024.102444

Celia Robles Cabanillas , Isabel Hurtado Navarro , Aníbal García-Sempere , Fran Llopis-Cardona , Francisco Sánchez-Sáez , Clara Rodríguez-Bernal , Gabriel Sanfélix-Gimeno

{"title":"Association of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study","authors":"Celia Robles Cabanillas , Isabel Hurtado Navarro , Aníbal García-Sempere , Fran Llopis-Cardona , Francisco Sánchez-Sáez , Clara Rodríguez-Bernal , Gabriel Sanfélix-Gimeno","doi":"10.1016/j.gaceta.2024.102444","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the risk of acute pancreatitis and biliary disease in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RA).</div></div><div><h3>Method</h3><div>Population-based, propensity-weighted, new user, active comparator design study including patients with diabetes and obesity initiating treatment with GLP-1 RA or the comparator group sodium-glucose cotransporter 2 inhibitors (SGLT-2i) in the region of Valencia from 2015 to 2021.</div></div><div><h3>Results</h3><div>In adjusted, per protocol main analysis, no risk differences were found for acute pancreatitis (HR: 0.56; 95%CI: 0.17-1.91) nor for biliary disease (HR: 1.12; IC95%: 0.79, 1.58). Secondary analyses yielded similar results.</div></div><div><h3>Conclusions</h3><div>Despite we did not observe increased risk of gastrointestinal events in GLP-1 RA vs SGLT-2i patients, adherence to approved indications and close monitoring of potential adverse events are warranted to ensure patient safety.</div></div>","PeriodicalId":12494,"journal":{"name":"Gaceta Sanitaria","volume":"39 ","pages":"Article 102444"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gaceta Sanitaria","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S021391112400102X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To evaluate the risk of acute pancreatitis and biliary disease in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RA).

Method

Population-based, propensity-weighted, new user, active comparator design study including patients with diabetes and obesity initiating treatment with GLP-1 RA or the comparator group sodium-glucose cotransporter 2 inhibitors (SGLT-2i) in the region of Valencia from 2015 to 2021.

Results

In adjusted, per protocol main analysis, no risk differences were found for acute pancreatitis (HR: 0.56; 95%CI: 0.17-1.91) nor for biliary disease (HR: 1.12; IC95%: 0.79, 1.58). Secondary analyses yielded similar results.

Conclusions

Despite we did not observe increased risk of gastrointestinal events in GLP-1 RA vs SGLT-2i patients, adherence to approved indications and close monitoring of potential adverse events are warranted to ensure patient safety.

查看原文本刊更多论文

胰高血糖素样肽-1受体激动剂与糖尿病和肥胖患者急性胰腺炎和胆道疾病的关联：一项倾向加权、基于人群的队列研究

目的：评价胰高血糖素样肽-1受体激动剂（GLP-1 RA）治疗患者发生急性胰腺炎和胆道疾病的风险。方法：以人群为基础，倾向加权，新用户，积极比较设计研究，包括2015年至2021年在瓦伦西亚地区开始接受GLP-1 RA或比较组钠-葡萄糖共转运蛋白2抑制剂（SGLT-2i）治疗的糖尿病和肥胖患者。结果：经调整后，在每个方案主要分析中，急性胰腺炎无风险差异(HR: 0.56；95%CI: 0.17-1.91)和胆道疾病(HR: 1.12；（95%: 0.79, 1.58）。二次分析得出了类似的结果。结论：尽管我们没有观察到GLP-1 RA与SGLT-2i患者胃肠道事件的风险增加，但有必要遵守批准的适应症并密切监测潜在的不良事件，以确保患者安全。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gaceta Sanitaria 医学-公共卫生、环境卫生与职业卫生

CiteScore

4.10

自引率

5.30%

发文量

审稿时长

29 days

期刊介绍： Gaceta Sanitaria (Health Gazette) is an international journal that accepts articles in Spanish and in English. It is the official scientific journal of the Sociedad Española de Salud Publica y Administración Sanitaria (Spanish Society of Public Health and Health Administration) (SESPAS). The Journal publishes 6 issues per year on different areas of Public Health and Health Administration, including: -Applied epidemiology- Health prevention and promotion- Environmental health- International health- Management and assessment of policies and services- Health technology assessments- Health economics. The editorial process is regulated by a peer review system. It publishes original works, reviews, opinion articles, field and methodology notes, protocols, letters to the editor, editorials, and debates.